Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Breast 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Other 1Genitourinary 1Gastrointestinal 1

Conditions

Radiation Injuries 1Prostatic Neoplasms 1

Interventions

Docetaxel 390pembrolizumab 325Prednisone 284Gemcitabine 273enzalutamide 254Radiotherapy 251Nivolumab 247Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 197Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 98cabozantinib 97abiraterone 97Sorafenib 97atezolizumab 96Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lisinopril × Genitourinary × Clear all
NCT05530655 2026-01-13

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

University of Rochester

Phase EARLY_PHASE1 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms, Radiation Injuries

Data powered by HemOnc (CC BY 4.0) Colophon âš¡